M&A Deal Summary

Concentra Biosciences Acquires Theseus

On December 22, 2023, Concentra Biosciences acquired life science company Theseus

Acquisition Highlights
  • This is Concentra Biosciences’ 2nd transaction in the Life Science sector.
  • This is Concentra Biosciences’ 2nd transaction in the United States.
  • This is Concentra Biosciences’ 2nd transaction in Massachusetts.

M&A Deal Summary
Date 2023-12-22
Target Theseus
Sector Life Science
Buyer(s) Concentra Biosciences
Deal Type Add-on Acquisition
Advisor(s) Leerink Partners (Financial)
Goodwin Procter (Legal)

Target

Theseus

Cambridge, Massachusetts, United States
Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies. The company is focused on the development of THE-349, a fourth-generation, selective epidermal growth factor receptor inhibitor for C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer, a pan-variant BCR-ABL inhibitor for the treatment of relapsed/refractory chronic myeloid leukemia and newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, and a next-generation, highly selective, pan-variant KIT inhibitor for the treatment of early-line GIST. Theseus is based in Cambridge, Massachusetts.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Concentra Biosciences

San Diego, California, United States
Category Company
Sector Life Science
DESCRIPTION

Concentra Biosciences is a biosciences company that serves clients around the US. Concentra Biosciences is based in San Diego, California.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 1
State (Massachusetts) 2 of 2
Country (United States) 2 of 2
Year (2023) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-03-27 Jounce Therapeutics

Cambridge, Massachusetts, United States

Jounce Therapeutics is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. It currently has multiple development-stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce Therapeutics is based in Cambridge, Massachusetts.

Buy -
Mergr

Product

Company

Legal